Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQWE7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $27,959
Award facts
- Contract value 100% obligated
- $27,959.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $27,959.04 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 300 mg/2 mL Xolair auto-injector vials. The delivery order, issued December 3, 2025, with an ultimate completion date of December 24, 2025, carries no set-aside designation, indicating the contractor competed in unrestricted federal procurement. DMS Pharmaceutical Group is the sole awardee with no identified subcontractors on this engagement.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceuticals and medical consumables to Department of Defense healthcare facilities worldwide. The underlying indefinite delivery contract, designated SPE2DR and valued at $499.999 billion, was awarded November 13, 2025, and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a critical supplier for military medical system operations globally. Xolair, an immunosuppressant biologic, aligns with the contractor's demonstrated capability across specialty pharmaceuticals and biologic agents supplied to federal military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FQWE7?
SPE2DR26FQWE7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FQWE7 worth?
The government has obligated $27,959 on SPE2DR26FQWE7.
Is contract SPE2DR26FQWE7 an order under another contract?
Yes. SPE2DR26FQWE7 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWE7 competed?
The extent of competition for SPE2DR26FQWE7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award